SENZUMODERN REBIRTHMy account Tirzepatide
Also known as Mounjaro · tirz · Zepbound
SURMOUNT-1 demonstrated substantial sustained weight reduction in adults with obesity or overweight plus a weight-related complication. The Zepbound label also includes moderate-to-severe obstructive sleep apnea in adults with obesity.
- Evidence maturity
- Established record
- Regulatory status
- FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 2
This profile does not recommend a compound, dose, supplier, or treatment plan. Discuss personal decisions with a qualified clinician who knows your history.
Summary
A dual GIP and GLP-1 receptor agonist with FDA-approved products for specific metabolic indications.
What is Tirzepatide being studied for?
Weight management and obesity-related sleep apnea
How is it thought to work?
Activates GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, appetite, caloric intake, and gastric emptying.
Recorded outcomes
3 graded outcomes and 2 sources for Tirzepatide.
The graded outcome table, how each grade was decided, the regulatory detail, and every source with its link and identifier open with a free account. No payment details required.
Update history
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.